Is Fermenta Biotech a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Fermenta Biotech Ltd is a below average quality company .

Is Fermenta Biotech undervalued or overvalued?

The key valuation ratios of Fermenta Biotech Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Fermenta Biotech share price return in the past 10 years?

Fermenta Biotech Ltd share price has appreciated 21.3% annually (CAGR) over the past ten years.

Is Fermenta Biotech a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Fermenta Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Fermenta Biotech Ltd - Stock Valuation and Financial Performance

Name: Fermenta Biotech
Brand: Fermenta Biotech

BSE: 506414 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Fermenta Biotech Share Price

₹406.85 43.10 11.85%
as on 03-Dec'24 16:59

10 Year X-Ray of Fermenta Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0.9%	-5.5%	-8.5%	-7.5%	43.5%	13.8%	14.5%	9.9%	-6.2%	2.6%	-
Value Creation Index ⓘ	-0.9	-1.4	-1.6	-1.5	2.1	0.0	0.0	-0.3	-1.4	-0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	13.5	6.1	5.5	12.5	405	301	373	388	329	307	341
Sales YoY Gr.	-	-54.6%	-10.1%	126.6%	3,134.8%	-25.7%	24.1%	4.1%	-15.2%	-6.6%	-
Adj EPS ⓘ	0.3	-3.3	-6.6	-7.2	42	21.8	17.7	9.6	-10.3	-4.6	2.6
YoY Gr.	-	-1318.5%	NA	NA	NA	-48.1%	-18.8%	-46.1%	-208.3%	NA	-
BVPS (₹) ⓘ	33.6	30	32.6	23.5	86.7	106.3	124.3	132.2	111.9	104.4	107.1
Adj Net Profit ⓘ	0.7	-9.1	-18.3	-19.9	116	62.9	51.1	27.6	-29.8	-13.3	8
Cash Flow from Ops. ⓘ	-0.4	-5	-9.1	1.3	90.5	29.8	63	50.4	124	105	-
Debt/CF from Ops. ⓘ	-93.3	-11	-4.9	107.9	2.3	7.4	3.6	4.7	1.8	1.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	41.5%	-5.4%	-6.3%	-6.6%
Adj EPS ⓘ	-237%	-164.2%	-163.8%	NA
BVPSⓘ	13.4%	3.8%	-5.6%	-6.7%
Share Price	21.3%	14.8%	11.1%	160.3%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	0.8	-10.3	-21.2	-25.8	73.6	22.4	15	7.2	-8.2	-4.1	2.5
Op. Profit Mgn % ⓘ	21.5	-98.9	-154	-26.5	35.5	23	25.7	19.8	12.1	12.3	15.5
Net Profit Mgn % ⓘ	5.5	-147.6	-331.3	-159.2	28.6	20.9	13.7	7.1	-9.1	-4.3	2.3
Debt to Equity ⓘ	0.4	0.7	0.5	2.2	0.9	0.7	0.6	0.6	0.7	0.4	0.1
Working Cap Days ⓘ	439	866	1,020	520	111	304	308	355	383	320	119
Cash Conv. Cycle ⓘ	-15	-24	-16	-20	35	129	141	168	171	117	36

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 2.50%

Debt to equity has declined versus last 3 years average to 0.44

Sales growth is good in last 4 quarters at 31.14%

Sales growth has been subdued in last 3 years -6.26%

Net Profit has been subdued in last 3 years -163.80%

Latest Financials - Fermenta Biotech Ltd.

	Standalone	Consolidated
TTM EPS (₹)	2.6	2.9
TTM Sales (₹ Cr.)	341	369
BVPS (₹.) ⓘ	107.1	98.6
Reserves (₹ Cr.) ⓘ	300	276
P/BV ⓘ	3.40	3.69
PE ⓘ	138.03	126.41

From the Market
52 Week Low / High (₹)	145.00 / 399.60
All Time Low / High (₹)	4.90 / 442.00
Market Cap (₹ Cr.)	1,071
Equity (₹ Cr.)	14.7
Face Value (₹)	5
Industry PE ⓘ	44.7

Management X-Ray of Fermenta Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Fermenta Biotech

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Fermenta Biotech

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	14	6	6	13	405	301	373	388	329	307
Operating Expenses ⓘ	11	13	14	24	277	232	278	311	290	270
Manufacturing Costs	2	2	4	6	41	34	44	55	50	53
Material Costs	0	0	0	0	92	83	124	144	126	105
Employee Cost	5	5	6	6	53	50	57	59	54	54
Other Costs ⓘ	4	6	5	12	90	65	53	53	60	57
Operating Profit ⓘ	3	-7	-9	-11	128	69	95	77	39	37
Operating Profit Margin (%)	21.4%	-108.0%	-154.0%	-90.1%	31.6%	22.8%	25.4%	19.8%	11.9%	12.2%
Other Income ⓘ	0	1	1	2	26	14	7	8	8	8
Interest ⓘ	0	2	6	11	21	20	19	18	21	17
Depreciation ⓘ	2	2	3	4	12	15	19	24	24	24
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	-60	-9
Profit Before Tax ⓘ	1	-9	-18	-23	121	48	63	43	-58	-5
Tax ⓘ	0	0	0	1	11	-16	11	12	-1	14
Profit After Tax	1	-9	-18	-24	110	64	52	30	-57	-19
PAT Margin (%)	5.4%	-148.0%	-331.0%	-193.0%	27.3%	21.2%	13.9%	7.8%	-17.3%	-6.1%
Adjusted EPS (₹)	0.3	-3.3	-6.7	-8.8	40.1	22.1	18.0	10.5	-19.8	-6.5
Dividend Payout Ratio (%)	157%	-6%	-3%	-2%	1%	23%	14%	12%	-6%	-19%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	92	83	90	65	249	307	358	381	323	301
Share Capital ⓘ	2	2	2	2	5	14	14	14	14	14
Reserves ⓘ	90	80	87	62	244	292	344	367	308	287
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	17	38	138	195	206	207	212	185	110
Long Term Debt	0	14	34	132	135	102	110	115	84	43
Short Term Debt	0	2	4	6	60	104	96	97	101	67
Trade Payables	1	1	1	2	43	47	46	46	52	53
Others Liabilities ⓘ	50	49	17	18	44	12	108	123	107	109
Total Liabilities ⓘ	143	149	146	223	532	572	719	762	667	573
Fixed Assets
Gross Block	22	100	9	13	128	163	315	293	320	376
Accumulated Depreciation	15	6	1	2	24	37	65	73	92	114
Net Fixed Assetsⓘ	7	94	8	12	104	126	250	220	228	261
CWIP ⓘ	63	1	1	0	22	71	57	35	45	2
Investmentsⓘ	40	41	31	108	76	72	13	13	15	4
Inventories	0	0	0	0	88	114	133	130	110	79
Trade Receivables	0	0	0	0	66	77	96	118	67	77
Cash Equivalents	16	3	1	2	91	32	41	31	55	57
Others Assetsⓘ	17	12	104	100	87	79	130	216	146	94
Total Assets ⓘ	143	149	146	223	532	572	719	762	667	573

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	0	-5	-9	1	91	30	63	50	124	105
PBT ⓘ	1	-9	-18	-23	121	48	63	43	-58	-5
Adjustment ⓘ	2	4	10	20	39	34	40	39	147	85
Changes in Working Capital ⓘ	-2	1	-2	5	-36	-38	-27	-22	31	23
Tax Paid ⓘ	-2	-1	1	-1	-33	-14	-13	-9	4	1
Cash Flow From Investing Activity ⓘ	-11	-8	20	-89	-97	-39	-44	-32	-64	-15
Capex	-28	-21	-8	-4	-35	-64	-55	-37	-40	-19
Net Investments	0	13	26	-84	-53	24	2	4	-16	4
Others ⓘ	17	0	2	-1	-9	1	9	1	-7	0
Cash Flow From Financing Activityⓘ	9	14	-13	88	12	-48	-1	-22	-41	-91
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	10	14	0	0	6	-34	14	3	-18	-47
Interest Paid ⓘ	0	-2	-6	-9	-20	-21	-18	-17	-20	-17
Dividend Paid ⓘ	-1	-1	-1	-1	-1	-6	0	-7	-4	-4
Others ⓘ	0	2	-6	98	28	13	2	-1	1	-23
Net Cash Flow ⓘ	-2	1	-2	1	6	-57	18	-4	19	-1

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	0.79	-10.44	-21.25	-31.3	72.78	23.36	15.63	8.18	-16.19	-6
ROCE (%)	0.87	-5.46	-8.47	-7.52	43.46	13.83	14.54	9.85	-6.18	2.56
Asset Turnover Ratio	0.1	0.04	0.04	0.07	1.07	0.54	0.58	0.52	0.46	0.5
PAT to CFO Conversion(x)	0	N/A	N/A	N/A	0.83	0.47	1.21	1.67	N/A	N/A
Working Capital Days
Receivable Days	7	6	14	10	30	87	85	101	103	86
Inventory Days	12	0	0	0	79	122	121	123	133	112
Payable Days	0	0	0	0	90	200	137	116	141	182

Fermenta Biotech Ltd Stock News

Fermenta Biotech Ltd FAQs

What is the share price of Fermenta Biotech?

Company share prices are keep on changing according to the market conditions. The closing price of Fermenta Biotech on 03-Dec-2024 16:59 is ₹406.9.

What is the market cap of Fermenta Biotech?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2024 16:59 the market cap of Fermenta Biotech stood at ₹1,070.6.

What is the P/E ratio of Fermenta Biotech?

The latest P/E ratio of Fermenta Biotech as of 03-Dec-2024 16:59 is 138.0.

What is the P/B ratio of Fermenta Biotech?

The latest P/B ratio of Fermenta Biotech as of 03-Dec-2024 16:59 is 3.40.

What is the 52-week high and low of Fermenta Biotech?

The 52-week high of Fermenta Biotech is ₹399.6 and the 52-week low is ₹145.0.

What is the TTM revenue of Fermenta Biotech?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fermenta Biotech is ₹341.2 ( Cr.) .

About Fermenta Biotech Ltd

DIL Ltd. formerly Duphar-Interfran Limited is an Indian public listed company located at Thane, India. Founded in 1951 by Late Dr. D V K Raju in the name of International Franchises Private Limited. DIL has built successful partnerships with leading multinational companies for over 53 years. The name of the company was then changed to â€˜Crookes Interfran Limitedâ€™ and then in 1971 the name was changed to â€˜Duphar Interfran Ltd.â€™. In the year 1976, the companyâ€™s equity shares were listed on the Stock Exchange of Bombay (BSE). In 2000, the company demerged its pharmaceutical business into a new company called Duphar Pharma India Ltd. (currently known as Solvay Pharma India Ltd.) which issued to the shareholders of Duphar Interfran Ltd., 2 equity shares of Duphar Pharma India Ltd. for every 1 share held in Duphar Interfran Ltd. by the shareholders at that time, while retaining their original share in Duphar Interfran Ltd. The name of the company was then changed to DIL Limited.

Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic.

With the growing global need for newer drugs and for research, DIL, with its capabilities, becomes a preferred partner for undertaking contract research and custom synthesis.

Specializing in synthesis of fine organic compounds, chiral building blocks and Intermediates, their expertise include developing small size, aromatic & non-aromatic, functionalized heterocycles, enzyme mediated asymmetric synthesis of hydroxyesters, protection of amino acids at amino and carboxyl functionalities and synthesis of compounds having peptide linkage.

From its fully-equipped and modern facilities, the multi-cultural team at DIL strives to offer the best services in organic synthesis and industrial biotechnology. Qualified synthetic chemists develop and produce tailor-made compounds (Gms to multi-kegs) for the pharmaceutical and biotechnology industries. Their services cover both individual projects, as well as working exclusively as permanent team members for clients.

Offering expertise on both short and long-term projects, DIL seamlessly blends in as an extension of the client company, offering flexible and integrated services, made to measure solutions, cost-effective and on-time service accelerating drug discovery and development â€“ backed by the assurance of confidentiality.

With all this, DIL enhances and adds value to the clientâ€™s research program. DIL is a public listed company delivering reliable services to the pharmaceutical and biotechnology industries. Tucked away in a quiet and verdant niche in Thane, (32 km. away from Mumbai), and spread over 28,000 sq mts of land, is where it all happens.

Business area of the company:

Milestones:

1951 â€“ 1963: Toll manufacturing for the pharmaceutical and cosmetics industries.
1963: The company established a JV with Philips Duphar for the manufacture and marketing of pharmaceutical products in India.
1976: DIL was listed on the Bombay Stock Exchange.
1980: Philips Duphar was taken over by Solvay Pharmaceuticals.
1986: Fermenta Biotech Ltd. was founded as a subsidiary company to complement and segregate DILâ€™s capabilities in biotechnology.
1987: Fundamental research was initiated as part of Solvayâ€™s research efforts. A full-fledged laboratory was set up as per GLP requirements and accredited by the Department of Scientific & Industrial Research.
1995: â€˜Crocinâ€™, which went on to become the most popular brand of paracetamol in India, was divested to SmithKline Beecham.
2000: The company realigned its business to focus sharply and exclusively on custom synthesis and process R&D by de-merging its pharmaceutical formulation business in favour of Solvay.